Yes, hydroxychloroquine is definitively classified as a disease-modifying antirheumatic drug (DMARD)
Hydroxychloroquine is explicitly categorized as a conventional synthetic DMARD (csDMARD) across all major rheumatology guidelines 1, 2, 3, 4, 2. This classification is consistent and unambiguous in the medical literature.
DMARD Classification Framework
Multiple authoritative guidelines confirm hydroxychloroquine's status:
- 2021 ACR Rheumatoid Arthritis Guideline: Lists hydroxychloroquine among conventional synthetic DMARDs alongside methotrexate, leflunomide, and sulfasalazine 1, 5
- 2019 EULAR RA Recommendations: Explicitly includes hydroxychloroquine in the csDMARD category 2
- 2022 EULAR Infection Screening Guidelines: Categorizes hydroxychloroquine separately from other csDMARDs (methotrexate, leflunomide) due to its milder immunomodulatory effects, but still acknowledges it as a DMARD 3
- 2021 ACR Juvenile Idiopathic Arthritis Guideline: Clearly identifies "HCQ = hydroxychloroquine" within the DMARD nomenclature 6
Mechanism and Clinical Role
Hydroxychloroquine functions as an immunomodulatory agent through multiple cellular pathways 7, 8, 9. It inhibits endolysosomal functions including autophagy, blocks endosomal Toll-like receptor activation, and reduces pro-inflammatory cytokine production 9. These mechanisms align with the fundamental definition of DMARDs as agents that modify disease processes rather than merely treating symptoms.
The drug is FDA-approved for rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus 10, which are classic DMARD indications.
Important Context for Your Clinical Scenario
However, hydroxychloroquine is NOT indicated for osteoarthritis and should not be used in this context 11. The 2019 ACR/Arthritis Foundation Guideline for Osteoarthritis Management strongly recommends against hydroxychloroquine for knee, hip, and/or hand OA 11. Well-designed RCTs in erosive hand OA demonstrated no efficacy 11, 12.
Critical Clinical Distinction
Your patient presents with:
- Tricompartmental knee osteoarthritis (mechanical joint disease)
- Positive ANA and anti-RNP antibodies (serologic autoimmunity)
- Elevated hsCRP
The presence of autoimmune serologies does NOT convert osteoarthritis into an inflammatory arthritis requiring DMARD therapy. Positive ANA occurs in up to 41.5% of RA patients 13 and can be found in the general population without clinical significance. Elevated hsCRP in knee OA does not reliably identify inflammatory synovitis on MRI and should not guide treatment decisions toward anti-inflammatory therapies 14.
Appropriate Management Path
If this patient truly has an inflammatory arthritis (not just OA with incidental positive serologies), then:
- Hydroxychloroquine would be classified as a DMARD
- But it would be among the least preferred csDMARDs for inflammatory arthritis
- Methotrexate is strongly preferred over hydroxychloroquine for RA 6, 1, 15
- Hydroxychloroquine has "only weak clinical and no structural efficacy" in RA 2
The fundamental question is whether this patient has inflammatory arthritis or osteoarthritis with coincidental serologic findings. This distinction must be made through clinical assessment of synovitis, pattern of joint involvement, and imaging findings—not serology alone. Only if true inflammatory arthritis is confirmed would DMARD therapy (preferably methotrexate, not hydroxychloroquine) be appropriate.